Repligen (NASDAQ:RGEN) Given New $200.00 Price Target at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its target price lowered by JPMorgan Chase & Co. from $230.00 to $200.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Several other analysts have also weighed in on the stock. KeyCorp raised their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a report on Thursday, February 15th. Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $197.75.

Repligen Price Performance

Shares of NASDAQ RGEN traded up $0.74 during mid-day trading on Thursday, hitting $167.05. 454,984 shares of the stock were exchanged, compared to its average volume of 538,521. The company has a market cap of $9.33 billion, a P/E ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03. The stock’s fifty day simple moving average is $180.81 and its two-hundred day simple moving average is $173.90. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 6.35. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The firm had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.64 EPS. As a group, analysts forecast that Repligen will post 1.46 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Anthony Hunt sold 16,707 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Ralf Kuriyel sold 3,517 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,597 shares of company stock valued at $5,039,532. 1.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Repligen

Several institutional investors have recently added to or reduced their stakes in RGEN. YHB Investment Advisors Inc. bought a new stake in Repligen in the 1st quarter valued at $26,000. Benjamin F. Edwards & Company Inc. lifted its position in Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares in the last quarter. Signaturefd LLC lifted its position in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 86 shares in the last quarter. Principal Securities Inc. bought a new stake in Repligen in the 4th quarter valued at $48,000. Finally, Milestone Investment Advisors LLC bought a new stake in Repligen in the 3rd quarter valued at $61,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.